Navigation Links
Perrigo Company to Present at The Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference
Date:7/7/2008

ALLEGAN, Mich., July 7 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO;TASE) announced today that Joseph C. Papa, Perrigo's Chairman and CEO will present at the Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference on Tuesday, July 8, at 4:05 p.m. (ET) at the Four Seasons Hotel in Boston. The presentation will be webcast on the following link http://www.veracast.com/webcasts/opco/consumer08/79112301.cfm

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).


'/>"/>
SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Perrigo Vice Chair Mori Arkin To Retire After 30 Years of Service
2. Perrigo Company to Host Analyst Meeting on September 18, 2007
3. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
4. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
5. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
6. Perrigo Company Will Release First Quarter Fiscal 2008 Results on November 1, 2007
7. Perrigo Company Announces Dividend Increase
8. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
9. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
10. Perrigo Acquires UK OTC Store Brand Supplier
11. Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 26, 2017 , ... Want to learn more about CRISPR-Cas ... that demonstrates how this advanced plant breeding technology is a more efficient way ... resources. It highlights the business’ principles, research and collaboration efforts in this area. ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, a medical ... that it has received 510(k) clearance from the U.S. Food & Drug Administration ... Pro. , Both devices are stationary cycling systems that use MYOLYN’s patent-pending ...
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab ... to be the preferred physical therapy provider for Derby City CrossFit, effective immediately. ... City CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will ...
(Date:4/25/2017)... IN (PRWEB) , ... April 25, 2017 , ... ... D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration could ... Financial will provide insight into what changes are most likely to make it ...
(Date:4/25/2017)... ... , ... Lake Park Dental is now accepting new patients with crooked teeth ... With the help of this highly-effective, yet convenient system, patients can straighten their teeth ... less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth Dy, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... ZappRx, Inc ., a digital health company focused on modernizing ... closed $25 million in Series B funding led by Qiming ... Seattle that is part of a broader ... round included participation from SR One , who led ... (formerly Google Ventures). As part of the financing, Mark ...
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
Breaking Medicine Technology: